瀏覽量: 135
- 產(chǎn)品名稱(chēng): Deruxtecan
- 產(chǎn)品貨號(hào): CS00468
- 貨期: 現(xiàn)貨
- 價(jià)格與訂購(gòu): 3000
- 數(shù)量:
- 規(guī)格: 1mg
- 產(chǎn)品信息
- 如何訂購(gòu)
產(chǎn)品描述
Deruxtecan is an ADC drug-linker conjugate composed of a derivative of DX-8951 (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
靶點(diǎn)活性
Camptothecins
體外活性
Antibody-drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic window[2].
別名
化合物Deruxtecan
純度
98%
分子量
1034.05
分子式
C52H56FN9O13
CAS No.
1599440-13-7
存儲(chǔ)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
溶解度
DMSO: 34 mg/mL (32.88 mM)
H2O: < 0.1 mg/mL (insoluble)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
參考文獻(xiàn)
1. NOGUCHI, Shigeru, et al. METHOD FOR SELECTIVELY MANUFACTURING ANTIBODY-DRUG CONJUGATE. WO2017002776A1.
2. Ogitani Y, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46.
Note
For research use only .